DK173015B1 - Human insulinanalog-kompleks og parenteral farmaceutisk formulering indeholdende dette - Google Patents

Human insulinanalog-kompleks og parenteral farmaceutisk formulering indeholdende dette Download PDF

Info

Publication number
DK173015B1
DK173015B1 DK199500677A DK67795A DK173015B1 DK 173015 B1 DK173015 B1 DK 173015B1 DK 199500677 A DK199500677 A DK 199500677A DK 67795 A DK67795 A DK 67795A DK 173015 B1 DK173015 B1 DK 173015B1
Authority
DK
Denmark
Prior art keywords
approx
human insulin
insulin
pharmaceutical formulation
zinc
Prior art date
Application number
DK199500677A
Other languages
Danish (da)
English (en)
Other versions
DK67795A (da
Inventor
Bruce Hill Frank
Henry Acken Havel
Diane Lee Bakaysa
Allen Howard Pekar
Davis Nettleship Brems
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22989969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK173015(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DK67795A publication Critical patent/DK67795A/da
Application granted granted Critical
Publication of DK173015B1 publication Critical patent/DK173015B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK199500677A 1994-06-16 1995-06-14 Human insulinanalog-kompleks og parenteral farmaceutisk formulering indeholdende dette DK173015B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26063494 1994-06-16
US08/260,634 US5474978A (en) 1994-06-16 1994-06-16 Insulin analog formulations

Publications (2)

Publication Number Publication Date
DK67795A DK67795A (da) 1995-12-17
DK173015B1 true DK173015B1 (da) 1999-11-15

Family

ID=22989969

Family Applications (1)

Application Number Title Priority Date Filing Date
DK199500677A DK173015B1 (da) 1994-06-16 1995-06-14 Human insulinanalog-kompleks og parenteral farmaceutisk formulering indeholdende dette

Country Status (39)

Country Link
US (1) US5474978A (ro)
JP (2) JP3171541B2 (ro)
KR (1) KR100382326B1 (ro)
CN (1) CN1105576C (ro)
AT (1) AT408720B (ro)
BE (1) BE1009408A5 (ro)
BR (1) BR9502795A (ro)
CA (1) CA2151560C (ro)
CH (2) CH689250A5 (ro)
CO (1) CO4410203A1 (ro)
CZ (1) CZ287484B6 (ro)
DE (1) DE19521720B4 (ro)
DK (1) DK173015B1 (ro)
ES (1) ES2091727B1 (ro)
FI (1) FI118207B (ro)
FR (2) FR2721214B1 (ro)
GB (1) GB2291427B (ro)
GR (1) GR1003004B (ro)
HK (1) HK1015138A1 (ro)
HU (1) HU227240B1 (ro)
IE (1) IE68853B1 (ro)
IL (1) IL114151A (ro)
IT (1) IT1276723B1 (ro)
LU (1) LU88626A1 (ro)
MY (1) MY115631A (ro)
NL (1) NL1000566C2 (ro)
NO (1) NO322128B1 (ro)
NZ (1) NZ272359A (ro)
PE (1) PE19496A1 (ro)
PL (1) PL181310B1 (ro)
PT (1) PT101722B (ro)
RO (1) RO113530B1 (ro)
RS (1) RS49577B (ro)
RU (1) RU2152399C2 (ro)
SE (1) SE509052C2 (ro)
SI (1) SI9500200A (ro)
TW (1) TW421596B (ro)
UA (1) UA26874C2 (ro)
ZA (1) ZA954943B (ro)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352050A (en) * 1992-07-27 1994-10-04 Choate John I M Keyboard arrangement to maximize typing speed and ease of transition from a QWERTY keyboard
US5498088A (en) * 1992-07-27 1996-03-12 Choate; John I. M. Keyboard arrangement to maximize typing speed and ease of transition from a qwerty keyboard
US5836705A (en) * 1992-07-27 1998-11-17 Choate; John I. M. Keyboard arrangement to maximize typing speed and data entry and to ease transition from a qwerty keyboard
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
DE69630527T2 (de) * 1995-06-30 2004-08-05 Novo Nordisk A/S Vorbeugung einer krankheit mit diabetes charakter
DE69708121T3 (de) * 1996-06-20 2012-05-16 Novo Nordisk A/S Halogenid-enthaltende insulinzubereitungen
CO4750643A1 (es) * 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
WO1999021578A1 (en) 1997-10-24 1999-05-06 Eli Lilly And Company Insoluble insulin compositions
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
WO1999034821A1 (en) * 1998-01-09 1999-07-15 Novo Nordisk A/S Stabilised insulin compositions
CZ20011133A3 (cs) * 1998-10-16 2001-08-15 Novo Nordisk A/S Insulinové přípravky pro plicní podávání obsahující menthol
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
PT1172114E (pt) * 1998-10-16 2005-02-28 Novo Nordisk As Preparacoes concentradas e estaveis de insulina para administracao pulmonar
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
JP2002529514A (ja) * 1998-11-18 2002-09-10 ノボ ノルディスク アクティーゼルスカブ フェノール及びクレゾールを要さない安定なインスリン水性調製物
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US6734162B2 (en) 2000-01-24 2004-05-11 Minimed Inc. Mixed buffer system for stabilizing polypeptide formulations
WO2002009639A2 (en) * 2000-07-31 2002-02-07 Bar Ilan University Methods and pharmaceutical compositions for healing wounds
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6737401B2 (en) * 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
JP4508646B2 (ja) 2002-01-09 2010-07-21 エミスフェアー・テクノロジーズ・インク ４−［（４−クロロ−２−ヒドロキシベンゾイル）アミノ］ブタン酸ナトリウムの多形体
US20040005999A1 (en) * 2002-03-07 2004-01-08 Andreasen Kasper Huus Polyamino acid-based particle insulin preparation
US20030211976A1 (en) * 2002-03-07 2003-11-13 Andreasen Kasper Huus Polyamino acid-based particle insulin formulation
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
CA2528741A1 (en) 2003-06-17 2004-12-23 Sembiosys Genetics Inc. Methods for the production of insulin in plants
BRPI0412252A (pt) * 2003-07-25 2006-09-19 Conjuchem Inc derivados de insulina de longa duração e métodos dos mesmos
CA2553392A1 (en) * 2004-01-16 2005-08-11 Biodel Inc Sublingual drug delivery device
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
EP1773351B1 (en) 2004-05-06 2019-04-24 Emisphere Technologies, Inc. Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
ES2586423T3 (es) * 2004-05-14 2016-10-14 Emisphere Technologies, Inc. Compuestos de aril cetona y composiciones para administrar principios activos
WO2005115341A2 (en) * 2004-05-27 2005-12-08 Advanced Bionutrition Corporation Microparticles for oral delivery
PL1773878T3 (pl) 2004-07-19 2015-07-31 Biocon Ltd Koniugaty insulina-oligomer, ich formulacje i zastosowania
AU2005271526B2 (en) 2004-08-03 2011-12-08 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US20060078622A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
PT2918286T (pt) * 2004-10-05 2020-03-27 Novo Nordisk As Formulação farmacêutica
US8263551B2 (en) 2004-11-22 2012-09-11 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
WO2006093222A1 (ja) * 2005-03-02 2006-09-08 Ajinomoto Co., Inc. インスリンの多量体形成阻害剤
JP5688496B2 (ja) 2005-08-29 2015-03-25 アラヴァ・バイオ‐テック・リミテッドＡｒａｖａ Ｂｉｏ‐Ｔｅｃｈ Ｌｔｄ． 糖尿病および皮膚の老化を予防および治療するための方法および組成物
RU2507196C2 (ru) 2005-09-19 2014-02-20 Эмисфире Текнолоджис, Инк. Кристаллические формы динатриевой соли n-(5-хлорсалицилоил)-8-аминокаприловой кислоты
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2007096332A1 (en) * 2006-02-21 2007-08-30 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
CA2649109A1 (en) 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
ES2554773T3 (es) 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
PL2134351T3 (pl) 2007-03-13 2017-10-31 Jds Therapeutics Llc Sposoby i kompozycje do przedłużonego uwalniania chromu
JP5526018B2 (ja) * 2007-03-21 2014-06-18 エミスフェアー・テクノロジーズ・インク アリルオキシおよびアルキルオキシ安息香酸送達薬剤
WO2008132229A2 (en) * 2007-04-30 2008-11-06 Novo Nordisk A/S Highly concentrated insulin solutions and compositions
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
US9241908B2 (en) 2007-10-16 2016-01-26 Biocon Limited Orally administrable solid pharmaceutical composition and a process thereof
AU2008318423B2 (en) 2007-11-02 2013-12-05 Emisphere Technologies, Inc. Method of treating vitamin B12 deficiency
WO2010014946A2 (en) 2008-07-31 2010-02-04 Case Western Reserve University Halogen-stabilized insulin
ES2477552T3 (es) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
JP2012506856A (ja) 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
MX2011007929A (es) 2009-01-28 2011-08-17 Smartcells Inc Sistemas basados en conjugados para entrega farmacologica controlada.
JP2012516340A (ja) 2009-01-28 2012-07-19 スマートセルズ・インコーポレイテツド 合成コンジュゲートおよびその使用
WO2010092218A2 (es) 2009-02-12 2010-08-19 Proyecto De Biomedicina Cima, S.L. Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabólicas
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
EP2408808A4 (en) 2009-03-20 2015-05-06 Smartcells Inc TERMINAL-FUNCTIONALIZED CONJUGATES AND THEIR USE
BR112012011403B8 (pt) 2009-11-13 2021-05-25 Sanofi Aventis Deutschland composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma
KR101972301B1 (ko) 2009-11-13 2019-04-25 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ－１ 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물
EP2523677A2 (en) 2010-01-11 2012-11-21 Healor Ltd. Method for treatment of inflammatory disease and disorder
CA2996757A1 (en) * 2010-02-24 2011-09-01 Emisphere Technologies, Inc. Oral b12 therapy
CA2809321C (en) 2010-08-30 2018-08-14 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
CN107759771A (zh) 2010-09-30 2018-03-06 索尔维公司 天然来源的环氧氯丙烷的衍生物
WO2012115641A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
WO2012119007A1 (en) 2011-03-01 2012-09-07 N21 Acquisition Holding, Llc Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
HUE027989T2 (en) 2011-08-29 2016-11-28 Sanofi Aventis Deutschland A pharmaceutical composition for use in glycemic control in patients with type 2 diabetes
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
KR20150021011A (ko) 2011-10-27 2015-02-27 케이스 웨스턴 리저브 유니버시티 초고도 농축된, 속효성 인슐린 유사체 제형
US10159735B2 (en) * 2012-06-26 2018-12-25 The Curators Of The University Of Missouri Photocleavable drug conjugates
EP2877200B1 (en) 2012-07-17 2019-05-08 Case Western Reserve University O-linked carbohydrate-modified insulin analogues
BR112015010799B1 (pt) 2012-11-13 2023-01-17 Adocia Composição em solução aquosa, e, formulação farmacêutica
CA2890048C (en) 2012-12-03 2022-05-03 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
CA2889165A1 (en) 2012-12-19 2014-06-26 Wockhardt Limited A stable aqueous composition comprising human insulin or an analogue or derivative thereof
JP2016505601A (ja) 2012-12-26 2016-02-25 ウォックハート リミテッド 医薬組成物
US9670162B2 (en) 2013-03-14 2017-06-06 The Board Of Trustees Of The Leland Stanford Junio Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof
TW201605489A (zh) 2013-10-25 2016-02-16 賽諾菲公司 賴谷胰島素（ｉｎｓｕｌｉｎ ｇｌｕｌｉｓｉｎｅ）的穩定調配物
EP3185887B1 (en) 2014-08-26 2021-03-10 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
SI3229828T1 (sl) 2014-12-12 2023-06-30 Sanofi-Aventis Deutschland Gmbh Formulacija s fiksnim razmerjem inzulin glargin/liksisenatid
TW201630622A (zh) 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
WO2017139337A1 (en) 2016-02-11 2017-08-17 Nutrition 21, Llc Chromium containing compositions for improving health and fitness
KR20190140048A (ko) 2017-06-01 2019-12-18 일라이 릴리 앤드 캄파니 신속-작용 인슐린 조성물
EP3740212A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
WO2019125878A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
BR112022007593A2 (pt) 2019-10-25 2022-08-23 Cercacor Lab Inc Compostos indicadores, dispositivos que compreendem compostos indicadores e métodos de fabricação e uso dos mesmos
CA3173417A1 (en) 2020-03-31 2021-10-07 Alborz Mahdavi Conjugates for selective responsiveness to vicinal diols
KR20230110505A (ko) 2020-11-19 2023-07-24 프로토머 테크놀로지스 인크. 방향족 붕소-함유 화합물 및 인슐린 유사체
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4608634A (en) * 1982-02-22 1986-08-26 Texas Instruments Incorporated Microcomputer with offset in store-accumulator operations
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
KR900701842A (ko) * 1988-07-20 1990-12-04 헨리 브뢰늄 인간 인슐린 동족체와 그를 포함하는 제제
JPH04502465A (ja) * 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
NZ232375A (en) * 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
ATE176482T1 (de) * 1993-06-21 1999-02-15 Novo Nordisk As Asp-b28-insulinkristalle
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability

Also Published As

Publication number Publication date
HU227240B1 (en) 2010-12-28
HUT73186A (en) 1996-06-28
FR2741078A1 (fr) 1997-05-16
CZ154295A3 (en) 1996-02-14
SE509052C2 (sv) 1998-11-30
NO322128B1 (no) 2006-08-21
CN1122248A (zh) 1996-05-15
ATA101695A (de) 2001-07-15
SE9502167D0 (sv) 1995-06-14
NL1000566C2 (nl) 1996-12-03
IE950436A1 (en) 1995-12-27
DE19521720A1 (de) 1995-12-21
DK67795A (da) 1995-12-17
ITMI951278A1 (it) 1996-12-14
FR2741078B1 (fr) 1998-08-07
NO952357L (no) 1995-12-18
IL114151A (en) 2000-09-28
GB9512038D0 (en) 1995-08-09
HU9501716D0 (en) 1995-08-28
FI118207B (fi) 2007-08-31
CZ287484B6 (en) 2000-12-13
GR950100229A (en) 1996-02-29
GR1003004B (el) 1998-11-05
NZ272359A (en) 1996-10-28
FI952931A0 (fi) 1995-06-14
FI952931A (fi) 1995-12-17
FR2721214B1 (fr) 1997-09-26
JP2001199899A (ja) 2001-07-24
IT1276723B1 (it) 1997-11-03
GB2291427B (en) 1998-09-16
NL1000566A1 (nl) 1995-12-18
CA2151560C (en) 2000-05-09
PT101722B (pt) 1997-02-28
RU2152399C2 (ru) 2000-07-10
PL181310B1 (pl) 2001-07-31
PE19496A1 (es) 1996-06-01
CH689935A5 (de) 2000-02-15
AT408720B (de) 2002-02-25
JP3171541B2 (ja) 2001-05-28
PT101722A (pt) 1995-12-29
BR9502795A (pt) 1996-03-12
SI9500200A (en) 1996-02-29
ES2091727A1 (es) 1996-11-01
IL114151A0 (en) 1995-10-31
SE9502167L (sv) 1995-12-17
LU88626A1 (fr) 1996-02-01
NO952357D0 (no) 1995-06-14
ZA954943B (en) 1997-09-14
UA26874C2 (uk) 1999-12-29
CA2151560A1 (en) 1995-12-17
CO4410203A1 (es) 1997-01-09
JPH083067A (ja) 1996-01-09
PL309098A1 (en) 1995-12-27
CH689250A5 (de) 1999-01-15
MY115631A (en) 2003-08-30
TW421596B (en) 2001-02-11
RS49577B (sr) 2007-04-10
DE19521720B4 (de) 2009-09-03
RO113530B1 (ro) 1998-08-28
KR100382326B1 (ko) 2003-07-07
RU95110109A (ru) 1997-05-10
AU694501B2 (en) 1998-07-23
US5474978A (en) 1995-12-12
FR2721214A1 (fr) 1995-12-22
HK1015138A1 (en) 1999-10-08
YU39695A (sh) 1997-08-22
ITMI951278A0 (it) 1995-06-14
AU2168095A (en) 1996-01-04
ES2091727B1 (es) 1998-02-01
GB2291427A (en) 1996-01-24
IE68853B1 (en) 1996-07-24
BE1009408A5 (fr) 1997-03-04
KR960000924A (ko) 1996-01-25
CN1105576C (zh) 2003-04-16

Similar Documents

Publication Publication Date Title
DK173015B1 (da) Human insulinanalog-kompleks og parenteral farmaceutisk formulering indeholdende dette
KR100386038B1 (ko) 단량체성인슐린유사체의제제
AU2002302409B2 (en) Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability
RU2540485C2 (ru) Препарат инсулина, содержащий метионин
US20100069292A1 (en) Insulin with a basal release profile
US20220184213A1 (en) Novel formulations
WO2011143421A1 (en) Insulin with a stable basal release profile
NO178914B (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat for behandling av Diabetes mellitus
US4652548A (en) Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
WO2011156476A2 (en) Insulin with a basal release profile
BE1013507A5 (fr) Formulations d'analogues de l'insuline.
AU731636B2 (en) Insulin analog formulations
RU2154494C2 (ru) Комплекс аналога инсулина и протамина, способ получения, фармацевтическая композиция и способ лечения диабета
RJoshi Rapid Acting Analogues in Diabetes Mellitus Management

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired

Expiry date: 20150614